Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
8-11-2014 12:00 AM

Investigating the Multiple Hit hypothesis of Parkinson disease
using transgenic LRRK2-R1441G rats
Komal T. Shaikh, The University of Western Ontario
Supervisor: Dr. Susanne Schmid, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Neuroscience
© Komal T. Shaikh 2014

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Behavioral Neurobiology Commons, and the Other Neuroscience and Neurobiology
Commons

Recommended Citation
Shaikh, Komal T., "Investigating the Multiple Hit hypothesis of Parkinson disease using transgenic
LRRK2-R1441G rats" (2014). Electronic Thesis and Dissertation Repository. 2333.
https://ir.lib.uwo.ca/etd/2333

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

INVESTIGATING THE MULTIPLE HIT HYPOTHESIS OF PARKINSON
DISEASE USING TRANSGENIC LRRK2R1441G RATS
(Thesis format: Monograph)

by

Komal Shaikh

Graduate Program in Neuroscience

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

The School of Graduate and Postdoctoral Studies
The University of Western Ontario
London, Ontario, Canada

© Komal Shaikh 2014

ii

Abstract
The ‘multiple hit’ hypothesis of Parkinson disease (PD) suggests that the combination of
several risk factors leads to the development of PD. Here, we explore the interaction
between two potential causes of PD; a genetic mutation in the leucine-rich repeat kinase 2
(LRRK2) gene and exposure to the neurotoxin, Paraquat. This project characterizes
transgenic BAC rats expressing human LRRK2 bearing the familial PD mutation,
R1441G. These rats were tested for PD-related deficits at 3, 6, 9 & 12 months. These rats
were then exposed to intraperitoneal injections of Paraquat. We hypothesized that
LRRK2R1441G rats will show increased vulnerability to Paraquat compared to wildtype
controls. Our results showed that LRRK2R1441G rats are not significantly different from
wildtype rats by the 12 month stage, suggesting that this mutation alone is insufficient to
manifest PD-like features in rats. In addition LRRK2R1441G rats failed to show increased
vulnerability to Paraquat administration.

Keywords
Parkinson disease, leucine-rich repeat kinase 2, genetic model, transgenic BAC rats,
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Chapter 1
1.1

Introduction

Parkinson disease (PD), the second most common neurodegenerative disease, is
characterized by the degeneration of dopaminergic neurons in the substantia nigra pars
compacta (SNpc) and the presence of proteinaceous inclusions, known as Lewy bodies.
Diagnosis of PD is based on distinctive motor features including resting tremor, rigidity,
bradykinesia and abnormal gait. Cardinal motor features occur relatively late in the time
course of the disease and by this time 60% of dopaminergic neurons have degenerated
and striatal dopamine (DA) content has been reduced by 80% (Bernheimer et al., 1973).
Although, PD is primarily a movement disorder, a series of nonmotor symptoms are also
associated with the disease and can precede motor symptoms by several years (Chen et
al., 2013). These symptoms can include loss of smell, sleep disorders, and constipation.
In addition, PD patients may present with cognitive symptoms, including depression,
anxiety and impaired memory (Emre, 2004).
Although the aetiology of Parkinson disease is not yet known, both genetic and
environmental factors have been shown to play a role in disease development. While
most cases of PD are sporadic, 5-10% are caused by familial mutations. Recently, the
mapping of 16 PD associated loci (PARK 1-16), and the discovery of several
corresponding genes has prompted renewed interest in genetic underpinnings of this
disease. Mutations in the LRRK2 gene are a common cause of familial PD and result in
PARK8 type of Parkinson disease (Paisan-Ruiz et al., 2004; Zimprich et al., 2004).
LRRK2 encodes leucine-rich-repeat kinase II, a large multidomain protein with both
kinase and GTPases enzymatic functions (Zimprich et al., 2004; Santpere and Ferrer,
2009). The R1441G mutation on LRRK2 is the second most common mutation and it
increases kinase activity through modulation of GTPase activity (Healy et al., 2008).
LRRK2 mutations cause a familial PD which is indistinguishable from sporadic PD
suggesting similar underlying mechanisms.
Exposure to environmental toxins, particularly agrochemicals, has also been linked to
PD, underscoring the complex aetiology of this disease. In particular, exposure to N,N’-
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dimethyl-4-4’-bipyridinium dichloride, or paraquat has been shown to increase PD risk
(Costello et al., 2009). Paraquat, a widely used herbicide, induces PD related
neuropathology through increased oxidative stress and production of reactive oxygen
species (ROS).
The relatively low incidence of familial PD, failure to recapitulate PD phenotypes in
genetic models and lack of singular environmental insult has prompted discussion that
PD may not have a singular cause and instead disease phenotypes may be the outcome of
multiple factors. The ‘multiple hit’ hypothesis of PD suggests that multiple risk factors
interact to induce the degenerative process, with the primary insult causing cellular stress
and all succeeding insults resulting in a loss of protective pathways which together lead
to neuronal death (Sulzer, 2007).
The aim of the present study was to determine if mutated LRRK2 would induce PD
phenotypes in a rat model. We characterized transgenic BAC rats expressing human
LRRK2 bearing the autosomal dominant PD mutation, R1441G. Due to the progressive
nature of PD, these rats were tested for motor and cognitive deficits, reminiscent of PD,
through developmental stages of 3, 6, 9 and 12 months. As far as we are aware, this is the
first study that characterizes transgenic BAC LRRK2R1441G rats. Furthermore, in order to
assess the ‘multiple hit’ hypothesis rats bearing the R1441G mutation were tested for
vulnerability to Paraquat poisoning. We hypothesized that rats would show motor and
cognitive symptoms of PD by 12 months of age and that these rats would have an
increased vulnerability to Paraquat poisoning, as compared to wildtype controls.

12

Chapter 2

2

Literature Review
2.1

Parkinson Disease

Parkinson disease (PD), first described by James Parkinson as ‘shaking palsy,’ is the
second most common neurodegenerative disease and the most common movement
disorder. Like many neurodegenerative diseases, PD incidence increases with age from
0.3% in the general population to 1% in the over 60 population (Dexter and Jenner,
2013). The relative risk of developing PD is higher in males, due perhaps to estrogen’s
neuroprotective properties. Although the disease manifests in slow progressive symptoms
over a wide clinical spectrum, PD diagnosis is based on impaired motor function which
shows responsiveness to dopaminergic medication. Classic motor features of the disease
include an high amplitude, low frequency (4-7 Hz) resting tremor, rigidity, bradykinesia
or slowness of movement, shuffling gait and postural instability. In addition to these
motor symptoms, PD is associated with various non-motor symptoms, including sleep
disorders, depression, sensory abnormalities, gastrointestinal dysfunction, sexual
dysfunction and cognitive decline (Langston, 2006). The frequency of non-motor
symptoms increases with disease severity and age, however, certain symptoms, including
loss of smell, depression and constipation, can often precede onset of motor dysfunction
(Chaudhuri et al., 2006). Cognitive impairment is common in the disease and negatively
impact quality of life in patients. Patients with PD show impaired procedural and working
memory, executive dysfunction, learning impairments and dementia (Williams-Gray et
al., 2006).
Motor dysfunction in PD originates from degeneration of neuromelanin pigmented
dopaminergic neurons in the substantia nigra pars compacta (SNpc) and subsequent
dennervation of dopaminergic input from the SNpc to the striatum. Loss of striatal
dopamine content accounts for many of the motor abnormalities noted in PD. Motor
symptoms only occur when 60% of dopaminergic SNpc neurons have degenerated and
80% of their axon terminals have been lost (Bernheimer et al., 1973). Another
characteristic feature of the disease is the presence of Lewy bodies, which are
proteinaceous inclusions, composed of α-synuclein. Although neuronal loss in the SNpc
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characterizes the disease, PD is associated with widespread neuropathology affecting
various extranigral structures including the dorsal motor nucleus of the vagus, reticular
formation, raphe nucleus, locus coeruleus, amygdala, hippocampus, and the
magnocellular nuclei of the basal forebrain (Braak et al., 2003; Dexter and Jenner, 2013).
In 2003, Braak and colleagues proposed a staging progression for PD-related pathology
which starts in the lower brain stem (Stage I) and progresses to the pons (Stage II), the
mesencephalon (Stage III), the basal prosencephalon (Stage IV) and finally to the
neocoertex (Stage V and VI). This model explains the progression of PD symptoms from
olfactory dysfunction early in the disease (due to damage to olfactory bulb in Stage I), to
motor dysfunction (due to damage to SNpc in Stage III), to cognitive decline noted in
advanced stages of the disease (due to damage to neocortex in Stage V, Figure 1).
Despite breakthroughs leading to better understanding of PD, the etiology of this disease
and the mechanisms underlying neurodegeneration remain elusive. Currently, a variety of
originating factors, including genetic predisposition, exposure to environmental toxins
and traumatic brain injury are thought to induce PD related phenotypes through several
pathological mechanisms including mitochondrial dysfunction, increased oxidative stress,
altered proteolysis and inflammatory change.
New insight into the disease was made possible by the discovery of several genetic
mutations which are associated with the development of PD. While most cases of PD
(90%) are considered idiopathic, these genetic mutations can explain a small percentage
(10%) of disease cases. A better understanding of genetically linked PD may also
improve our understanding of idiopathic PD. PD associated genes may exert their effect
through a variety of pathological mechanisms such as forming protein aggregates (SNCA
genes), disrupting protein degradation (Parkin and UCHL1), protein misfolding (DJ-1),
impairment of lysosomal function (ATP13A2) and mitochondrial dysfunction (PINK1,
LRRK2).
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Figure 1: Progression of Parkinson disease.
The progression of Parkinson disease, according to the Braak Hypothesis. Lewy
pathology follows a caudo-rostral path from the lower brain stem, through susceptible
regions of the mid brain and forebrain, into the cerebral cortex (modified from Schneider
and Obeso, 2014).
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2.2
LRRK2: molecular structure, physiological role,
and distribution
Mutations in the leucine-rich repeat kinase-2 gene (LRRK2/PARK8) lead to autosomal
dominant PD which is clinically indistinguishable from sporadic PD, suggesting similar
underlying pathways (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). The leucine-rich
repeat kinase-2 gene codes for an eponymous, large intracellular protein with multiple
domains (Figure 2). LRRK2 is a member of the ROCO family of proteins and has two
conserved domains that are characteristic of this protein family: a Ras of complex
proteins (ROC) domain, and a C-terminal of ROC (COR) domain (Zimprich et al., 2004).
The function of the COR domain is not known, however the ROC domain functions as a
dimeric GTPase (Deng et al., 2008). In addition, several other conserved domains were
identified in this protein, including a leucine-rich repeat (LRR), a kinase domain, a
WD40 domain, and an ankyrin (ANK) repeat (Paisan-Ruiz et al., 2004; Zimprich et al.,
2004). The leucine-rich repeat, WD40 domain, and ANK repeat are common features in
many proteins and are thought to allow protein-protein interactions (Santperre and Ferrer,
2009), suggesting that LRRK2 may serve as a scaffold for the assembly of protein
complexes (Tsika and Moore, 2013). The kinase domain of LRRK2 is a member of the
super-family of serine and tyrosine kinases and has a similar structure to receptorinteracting protein (RIP) kinases, which are involved in activating cell death pathways in
response to intracellular and extracellular signals (Meylan and Tschopp, 2005). The
kinase activity of the protein is intramolecularly activated by the GTPase activity of the
ROC domain (Guo et al., 2007; Ito et al., 2007). In vivo LRRK2 presents as a dimer, in
which the ROC domain interactions with the LRR domain and the WD40 domain
(Greggio et al., 2008). The numerous functional motifs found in LRRK2 suggest that this
protein regulates a variety of cellular processes including mitochondrial function, signal
transduction, cell death pathways, vesicle trafficking, neurite outgrowth, autophagy and
cytoskeleton assembly (Santperre and Ferrer, 2009; Cookson et al., 2010; Berwick et al.,
2011; Tsika and Moore, 2012).
In adult humans, LRRK2 mRNA and protein is expressed in several tissues including the
brain, lungs, liver, kidney, spleen and in low levels in the heart (Paisan-Ruiz et al., 2004;
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Zimprich et al 2004; Miklossy et al., 2006; Westerlund et al., 2008). Within the brain
LRRK2 mRNA and protein expression is highest in the striatum, but is also found in the
frontal cerebal cortex, hippocampus, cerebellum, locus coreulus and the substantia nigra
(Galter et al., 2006; Higashi et al., 2007b; Westerlund et al., 2008; Vitte et al., 2010).
Within the neuron, LRRK2 localizes in a variety of structures including the mitochondria,
the endoplasmic reticulum, lysosomes and the cytoplasm (Biskup et al., 2006; AlegreAbarratequi et al., 2009; Vitte et al., 2010). In addition to localizing in these subcellular
structures in the cell body, LRRK2 is also found in dendrites and axonal processes
(Higashi et al., 2007b). In the PD brain, overall neuronal expression of LRRK2 mRNA
does not differ significantly from control brains (Sharma et al., 2011), however the
LRRK2 protein has been shown to be a component of Lewy bodies in the brainstem, the
substantia nigra and the locus coreulus (Higashi et al., 2007b; Vitte et al., 2010; Sharma
et al., 2011), though results can differ depending on the antibody used. Despite no change
in LRRK2 mRNA expression between control and PD cases in the frontal cortex, LRRK2
protein expression is enhanced in sporadic PD patients, suggesting post-transcriptional
modification or a failure to clear proteins (Cho et al., 2013).
LRRK2 mRNA and protein expression is relatively abundant in almost all brain regions
in the mouse brain including the striatum, cortex and the substantia nigra (SimonSanchez et al., 2006; Higashi et al., 2007a; Melrose et al., 2007; Giesert et al., 2013). In
contrast, LRRK2 mRNA expression in the rat brain is more restricted. In adult rat brains,
high expression has been noted in the medium spiny neurons of the striatum (Galter et al.,
2006; Taymans et al., 2006; Westerlund et al., 2008), the pyramidal neurons of cerebral
cortex (Taymans et al., 2006; Westerlund et al., 2008), the piriform cortex (Westerlund et
al., 2008), the hippocampus (Taymans et al., 2006) and in the sensory dorsal root
(Westerlund et al., 2008). Lower levels of LRRK2 mRNA have also been noted in the rat
hypothalamus, olfactory bulb and substantia nigra (Taymans et al., 2006). In rats,
temporal expression of LRRK2 in the striatum mirrors the postnatal development of
dopamine innervations of the striatum which underscores the link of LRRK2 to
dopaminergic neurons and the importance of LRRK2 malfunction in PD pathogenesis
(Westerlund et al., 2008).
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Figure 2: LRRK2 Structure.
LRRK2 is multi-domain protein with a catalytic core (ROC-COR-kinase) surrounded by
protein-protein interaction domains (ANK, LRR and WD40). Most pathogenic mutations
affect the GTPase and kinase activity of this protein. LRRK2 has been implicated in a
variety of cellular roles including mitochondrial function, vesicular trafficking,
neurotransmission, cell death pathways, cytoskeleton organization (modified from Tsika
and Moore, 2012).
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2.3

PD Related LRRK2 Mutations

Since the discovery of the link between LRRK2 and Parkinson disease, six mutations
have been identified in the LRRK2 gene with several other mutations increasing PD risk
(Zimprich et al., 2004; Berg et al., 2005; Di Fonzo et al., 2005; Goldwurm et al., 2005; Di
Fonzo et al., 2006; Clark et al., 2006; Santpere and Ferrer, 2009; Zhang et al., 2009; Seki
et al., 2011; Bozi et al., 2013; Anfossi et al., 2014; De Ross et al., 2014). Together these
LRRK2 mutations account for 13% of familial PD cases and 5% of sporadic cases (Berg
et al., 2005; Santpere and Ferrer, 2009). These pathogenic mutations have been found in
the kinase (G2019S, I2020T), ROC (R1441C/G/H), LRR (I1122V) and COR (Y1699C)
domains (Santpere and Ferrer, 2009). Regardless of the domain of origin, many
pathogenic mutations alter the kinase and GTPase activity of LRRK2 suggesting that
these functions are particularly important in PD pathogenesis (Li et al., 2007; Deng et al.,
2008; Anand and Braithwaite, 2009; Greggio, 2012; Biosa et al., 2013; Tsika and Moore,
2013; Ray et al., 2014).
The most common mutation, G2019S, is found in the kinase domain and increases the
kinase activity of the LRRK2 protein by forcing the protein to remain in an active state
(Berg et al., 2005; Funayama et al., 2005; Toft et al., 2005). When kinase capabilities of
LRRK2 are genetically inactivated, cellular phenotypes including neuronal death and
protein inclusions are greatly reduced, suggesting that kinase activity plays a crucial role
in cell toxicity (Greggio et al., 2006; Smith et al., 2006; Iaccarino et al., 2007). The
G2019S mutation may induce hyperphosporylation of tau, which in turn results in
dendrite degeneration (Lin et al., 2010). The kinase domain has also been shown to
phosphorylate sequences within the ROC domain, and therefore may regulate the GTPase
activity of LRRK2 (Greggio et al., 2008; Pungaliya et al., 2010).
The second most common site of PD related LRRK2 mutations is the R1441 “hotspot”
amino acid codon where glycine, histidine and cysteine substitutions can occur. The
R1441C/G/H mutations are in the ROC domain and affect the GTPase activity of the
protein. The LRRK2 protein shows low intrinsic GTPase activity, however, this may be
increased in vivo through binding with co-factors (Guo et al., 2007; West et al., 2007).
Interestingly, mutations within the GTPase domain, including R1441G, increase kinase
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activity through alteration of GTPase activity (West et al., 2007; Greggio et al., 2012;
Tsika and Moore, 2013; Liao et al., 2014; Muda et al., 2014). Taken together, evidence
suggests that the pathogenic effect of LRRK2 mutations depends on interplay between
the GTPase and kinase activities of the protein. However, the intrinsic regulation which
leads to LRRK2 toxicity remains unclear.

2.4

Genetic LRRK2 Animal Models

Modeling PD in animals can extend our understanding of etiology, pathogenesis and
development of Parkinson disease. Currently, PD therapies are symptomatic and do not
address the underlying pathogenic processes. A comprehensive animal model that
recapitulates the full spectrum of the disease would allow the development of therapeutic
strategies which specifically targeted the pathogenic process. Drosophila LRRK2 models
of Parkinson disease have recapitulated many features of PD including reduced dopamine
content, neuronal loss, mitochondrial abnormalities, and decreased locomotor activity
which can be ameliorated by L-DOPA (Imai et al., 2008; Liu et al., 2008; Ng et al., 2009;
Venderova et al., 2009). In addition, C.elegans models of LRRK2 mediated PD indicate
age-dependent dopaminergic neurodegeneration, behavioural deficits and locomotor
dysfunction (Yao et al., 2010). The success of these invertebrate models of Parkinson
disease has prompted their validation in mammals. Several rodent models test the
pathophysiology of LRRK2 in Parkinson disease, as well as attempt to recapitulate
cardinal features of the disease. Aberrant LRRK2 in Parkinson disease is thought to
mediate neurotoxicity through a gain of function, perhaps due to an increase in kinase
activity. Knock in and knock out models can provide support for this hypothesis by
investigating the function of neuronal system under abnormal levels of LRRK2. Indeed,
LRRK2 knockout mice display intact dopaminergic function and an absence of PD
related phenotypes (Andres-Mateos et al., 2009; Tong et al., 2010; Hinkle et al., 2012),
suggesting that an increase in the activity of LRRK2 is required for disease pathogenesis.
Recently transgenic mouse models have been developed that carry missense PD related
LRRK2 mutations. These models may provide unique insight into the mechanisms
through which familial LRRK2 mutations cause PD pathogenesis. Li and colleagues
describe a LRRK2R1441G BAC transgenic mouse line that recapitulates human PD
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phenotypes (Li et al., 2009). These mice showed L-DOPA responsive, age dependent
motor deficits starting at 6 months of age and progressively worsening by 12 months of
age (Li et al., 2009). While these animals did not show dopaminergic neuron
degeneration in the SNpc or aggregation of α-synuclein, dopamine release was impaired
in these animals and axonal dystrophy reminiscent of PD was noted in the striatum (Li et
al., 2009). Following studies with LRRK2R1441G mice have largely failed to reproduce the
motor dysfunction originally noted, however, mild Parkinsonism, gastrointestinal
dysfunction , a common non-motor feature of PD, and impaired dopaminergic
transmission have since been reported in some transgenic models (Bichler et al., 2013;
Dranka et al., 2013). LRRK2G2019S rodents have shown similarly mixed results with some
groups reporting PD related phenotypes, including degeneration of dopaminergic
neurons, hypoactivity, and impaired adult neurogenesis (Winner et al., 2011; Chen et al.,
2012), while others fail to recapitulate key features of the Parkinsonian process including
neurodegeneration (Zhou et al., 2011; Chou et al., 2014) and impaired locomotor ability
(Ramonet et al., 2011). Overall these transgenic rodent models fail to display substantial
PD pathology. One explanation for these results may be that multiple factors, such as
interactions with other genes or environmental stressors are required to inhibit
compensatory mechanisms and facilitate the degenerative process.

2.5
Mechanisms of LRRK2-mediated
neurodegeneration
Although the underlying mechanisms through which LRRK2 mediates PD pathogenesis
are still unclear, the molecular structure and distribution of LRRK2 can provide some
insight into cellular pathways which are compromised in familial mutations. The
presence of multiple protein-protein interaction domains in LRRK2 (ANK, LRR, WD40)
suggest that it plays a role in maintaining the integrity of the cytoskeleton. In PD,
degeneration of dopaminergic neurons in the SNpc is preceded by a loss of dopaminergic
axonal projections from the substantia nigra into the striatum. Recent studies suggest that
LRRK2 may play a role in the maintaining neuronal process integrity. Overexpression of
LRRK2 mutants results in a reduction in neurite length, axonal arborization, and the
formation of tau-positive inclusions, which eventually lead to neuronal death (MacLeod
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et al., 2006; Parisiadou et al., 2009; Ramonet et al., 2011; Sepulveda et al., 2013).
Conversely, suppression of LRRK2 results in the opposite phenotype of increased neuron
process length, suggesting that LRRK2’s normal role in maintaining neuronal process
integrity is disrupted by familial mutations (MacLeod et al., 2006; Parisiadou et al.,
2009). While it is still unclear how LRRK2 alters neurite morphology, the protein has
been shown to interact with ezrin/radixin/moesin (ERM) family of proteins and Rac1,
which are implicated in cell motility and actin skeletal dynamics (Parisiadou et al., 2009;
Chan et al., 2011). In addition, the ROC domain in LRRK2 interacts with β-tubulin and
this interaction is disrupted by the R1441G mutation, suggesting a role for LRRK2 in
microtubule stability (Gandhi et al., 2008; Gillardon et al., 2009; Law et al., 2014).
Neurite remodeling in LRRK2 mediated PD might be a result of autophagic imbalance.
Plowey et al. (2008) found that neurite retraction, in G2019S LRRK2 expressing
neuroblastoma cells, was significantly reduced when proteins necessary for autophagic
induction were suppressed. Impaired autophagic imbalance, specifically the accumulation
of large autophagic vacuoles with incompletely degraded materials, have since been
reported by various groups in both cells cultures (Alegre-Abarratequi et al., 2009;
Manzoni et al., 2013; Schapansky et al., 2014) and animal models (Ramonet et al., 2011;
Saha et al., 2014). The role of LRRK2 in autophagy may be of particular importance as
disrupted autophagy has been known to induce neuronal death (Komatsu et al., 2006).
Another mechanism through which LRRK2 is proposed to mediate neurodegneration is
through an increase in oxidative stress caused by mitochondrial dysfunction. The
localization of LRRK2 to the outer mitochondrial membrane supports this hypothesis
(Biskup et al., 2006). Wildtype LRRK2 seems to offer protection against agents that
cause mitochondrial dysfunction including Rotenone, Paraquat, hydrogen peroxide and 6OHDA (Ng et al., 2009; Saha et al., 2009; Nguyen et al., 2010; Pereira et al., 2014).
Conversely, familial mutations in LRRK2 do not offer protection against these agents and
are associated with an increased level of ROS and mitochondrial dysfunction (Iaccarino
et al., 2007; Ng et al., 2009; Saha et al., 2009; Heo et al., 2010; Nguyen et al., 2010;
Pereira et al., 2014). The increased vulnerability of LRRK2 mutants to oxidative stress
may be caused by the interaction of mutated LRRK2 with dynamin like protein 1 (DLP1)
which is a regulator of mitochondrial fission (Niu et al., 2012; Wang et al., 2012). These
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results suggest that LRRK2’s normal protective role against oxidative stress is
compromised with familial mutations, thus providing a mechanism through which these
mutations induce PD. While these studies have increased our understanding of cellular
pathways implicated in LRRK2 mediated neurodegeneration, it is important to note that
LRRK2 is a complex protein with several physiological functions and that PD
phenotypes are likely a combination of dysfunction across cellular processes.

2.6

Environmental Toxins and PD

In addition to genetic causes, the development of Parkinson disease has been linked to
exposure to environmental toxins, particularly agrochemicals that possess neurotoxicity
(Allen and Levy, 2013). In 1983, a small group of young individuals presented with PD
following 1-methly-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication (Langston
et al., 1983). The discovery of toxin triggered parkinsonism prompted investigation into
the association between the disease and environmental contaminants with several studies
showing an increased risk for PD following pesticide exposure (Brown et al., 2006;
Tanner et al., 2011; Liew et al., 2014). One of the many agrochemicals implicated in PD
pathogenesis is Paraquat. Paraquat, or N,N’-dimethyl-4-4’-bipyridinium dichloride, is a
widely used herbicide and pre-harvest desiccant. Paraquat’s chemical structure
resembles that of MPP+ (1-methyl-4-phenylpyridium), the active metabolite of the
neurotoxin MPTP. This chemical homology has prompted several studies to explore the
causative connection between Paraquat exposure and Parkinson disease. Epidemiological
studies investigating a correlation between Paraquat exposure and PD have yielded
inconclusive results (Costello et al., 2009, Firestone et al., 2005, Pezzoli and Cereda,
2013, Tanner et al., 2011), perhaps due in part to the challenges in exposure assessment.
However, human studies investigating Paraquat exposure in combination with other risk
factors (such as exposure to chemical agents and traumatic brain injury) have
demonstrated an increased PD risk (Brown et al., 2006; Peng et al., 2007; Costello et al.,
2009; Tanner et al., 2011; Lee et al., 2012). In addition, Paraquat induced PD phenotypes
such as dopaminergic neurodegeneration, substantia nigra reduction, decreased striatal
tyrosine hydroxylase immunoreactivity and alpha-synuclein accumulation, have been
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shown in animal studies (Chicchetti et al., 2005; Ossowska et al., 2006; Somayajulu-Nitu
et al., 2009; Kumar et al., 2010; Singhal et al; 2011).
In plants, Paraquat interacts with photosystem 1 to generate reactive oxygen species
(ROS). This results in increased toxicity due to excess ROS as well as inhibition of
photosynthesis and CO2 fixation. In rodents, Paraquat is able to cross the blood-brain
barrier (BBB) through a carrier-mediated mechanism involving the neutral amino acid
transporter (Shimizu et al., 2001). Recently, epidemiological studies have shown an
increased risk for Paraquat induced PD in patients with genetic variants in the dopamine
transporter (DAT), suggesting a role for DAT in Paraquat toxicity (Ritz et al., 2009).
Paraquat in its native state is a divalent cation, PQ2+, however it can be reduced by
NADPH oxidase to the monovalent cation, PQ+. PQ+ is a DAT substrate and can
accumulate in dopaminergic neurons leading to increased oxidative stress and
cytotoxicity (Rappold et al., 2011). In addition, PQ+ is a substrate for the organic cation
transporter 3 (Oct3) which is expressed in non-DA cells in the substantia nigra (Rappold
et al., 2011). Within the neuron, Paraquat’s exact mechanism of action is poorly
understood. However, Paraquat’s toxicity is thought to be the result of excess generation
of reactive oxygen species. Paraquat can be continuously oxidized and reduced (a process
known as redox cycling) to produce superoxide molecules. Acute Paraquat exposure has
been linked to excess production of intracellular ROS leading to cell apoptosis (Peng et
al., 2004). Paraquat interacts with complex I and III of the electron transport chain
resulting in an increase in H2O2 production (Drechsel and Patel, 2009). In addition,
Paraquat may induce dopaminergic neuronal death through activation of the JNK
pathway (Peng et al., 2004), and inhibition of autophagy (Wills et al., 2012).

2.7

Multiple Hit Hypothesis

Despite extensive research, the etiology of Parkinson disease remains unknown. Due to
the relatively low incidence of familial PD (5-10%), it seems unlikely that a genetic
mutation is sufficient to explain disease pathogenesis. Conversely, researchers have yet to
discover a single shared insult in PD patients as epidemiological studies often report
conflicting information. Taken together, this suggests that PD originates not from a
singular cause, but from multiple causes working synergistically to induce disease
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phenotypes. The ‘multiple hit’ hypothesis suggests that multiple risk factors interact to
induce the degenerative process seen in Parkinson disease (Sulzer, 2007). A variety of
factors have been shown to increase PD risk including aging (Driver et al., 2009; Collier
et al., 2011), genetic mutations (Ross et al., 2008; Alcalay et al., 2010; Bonifati, 2010;
Kim et al., 2010; Pan et al., 2012), exposure to environmental toxins (Baldereschi et al.,
2003; Phillipson, 2014) and trauma to the brain (Hubble et al., 1993; Doder et al., 1999;
Maher et al., 2002; Lee et al., 2012). In addition, several environmental factors such as
smoking, alcohol consumption, caffeine consumption, and exercise seem to have a
protective effect on PD risk (Saaksjarvi et al., 2014; Van der Mark et al., 2014; Zhang et
al., 2014), which suggests that environment does play an important role in the
development of this disease. The primary insult is proposed to result in cellular stress,
while secondary insults result in the loss of protective pathways thus inducing neuronal
death (Sulzer, 2007). Recently, several studies have provided supported for this
hypothesis. In rodent models of toxin-induced PD, multiple toxins working in
conjunction were shown to enhance PD neuropathology, including nigrostriatal
dopaminergic cell loss and reduced striatal dopamine content (Thiruchelvam et al., 2003;
Peng et al., 2007; Kumar et al., 2010). This is further supported by epidemiological
studies which show an increased PD risk in individuals exposed to multiple
agrochemicals (Tanner et al., 2011). Similarly, gene-environmental interactions have
been shown to play an important role in the development of PD. Peng et al. (2010)
showed that mice expressing the A53T familial mutant form of human α-synuclein
showed increased susceptibility to neonatal iron feeding and Paraquat exposure. Nuber et
al (2014) found that Paraquat exposure synergistically induced dopaminergic cell
degeneration in mice overexpressing familial PD linked mutant α-synuclein. In addition,
exposure to neurotoxins, maneb and Paraquat, alters regulation of adult neurogenesis in
transgenic mice carrying the SNCA and LRRK2G2019S familial mutations (Desplats, 2012).
In an epidemiological study, Ritz et al. (2009) found that individuals with dopamine
transporter genetic variations showed an increased risk for PD following exposure to
maneb or Paraquat. The combination of injury and exposure to environmental toxins has
also been shown to increased PD risk. Hutson et al. (2011) showed that traumatic brain
injury in adult rats increased vulnerability to Paraquat and caused degeneration of
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dopaminergic SNpc neurons. This was later supported by an epidemiological study which
noted increased incidence of PD in patients with traumatic brain injuries that had
previously been exposed to Paraquat (Lee et al., 2012). These studies suggest that
aetiology of Parkinson disease is a multifactorial. Animal models which explore the
synergistic effect of combined PD risk factors can play an important role in furthering
understanding of disease etiology.
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Figure 3: Multiple factors affect PD.
A proposed mechanism of multiple factors working in conjunction to induce Parkinson
disease. Genetic predisposition for the disease can prime neurons for additional stress
caused by environmental factors such as exposure to toxins or traumatic brain injury,
which then leads to neurodegeneration. Protective environmental factors can reduce the
likelihood of developing disease phenotypes. Adopted from Chen et al., 2013.
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Chapter 3

3

Research Purpose and Hypotheses

The purpose of this study was to investigate the combined effect of a genetic
predisposition and exposure to environmental toxins in the development of Parkinson
disease. Transgenic rats expressing the human LRRK2R1441G mutation were tested for
motor and cognitive deficits, reminiscent of PD, in order to determine if a genetic
mutation alone was sufficient to induce disease pathology. These rats were then exposed
to the neurotoxin, Paraquat in order to test increased susceptibility of transgenic rats to
environmental toxins. We hypothesized that LRRK2R1441G rats show PD phenotypes by 12
months of age and that these rats will have an enhanced susceptibility to Paraquat.
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4

Materials and Methods
4.1
Study 1: Assessing PD-related phenotypes in
LRRK2R1441G transgenic rats

4.1.1

Animals

A commercially available breeding pair of Sprague Dawley rats expressing the R1441G
mutation on the human gene LRRK2 was obtained from Taconic (Line #10677). The
original model was created by Dr. Chenjian Li through pronuclear injection of the human
LRRK2R1441G gene into Sprague Dawley zygotes. The line was maintained through in
house breeding of hemizygous x wildtype breeding pairs. More information about the
transgenic rat line used in this document can be found at http://www.taconic.com/10681.
Rats were weaned at 3 weeks of age and genotyped to detect human LRRK2. Transgenic
animals were housed with wildtype littermates in a 12 h light-dark cycle with food and
water provided ad libitum. 17 wildtype and 24 LRRK2R1441G transgenic rats underwent a
battery of behavioral tests. Animals underwent behavioral tests at 3 months, 6 months, 9
months and 12 months of age. All animals were tested on each behavioural test described
below at each of the four time points. All procedures were in accordance with the ethical
guidelines of the Canadian Council on Animal Care (CCAC) and approved by the
University of Western Ontario Animal Use Subcommittee.

4.1.2

Genotyping

Before weaning, all rats were genotyped by polymerase chain reaction (PCR) using tissue
obtained from ear-punching. Genotyping was performed using an assay kit from Taconic
according to their specifications. The PCR reaction combined 5 µL of genomic DNA (2
ng/µL), 2.5 µL of PCR Buffer (5 mM), 1 µL of MgCl2 (2.5 mM), 0.5 µL of
deoxynucleotide mixture (0.2 mM), 0.5 µL of hpark8-F primer (0.5µM), 0.5 µL of
hpark8-R primer (0.5µM) and 0.25 µL of HotStarTaq DNA Polymerase (0.05U/µL). The
thermocycler protocol involved 1 cycle (15 min) at 95ºC, combined 35 cycles with 45 s at
94ºC, 1 min at 65ºC, and 1 min at 72ºC, and 1 cycle at 72ºC (5 min). The primer
sequence for the hpark8-F primer is GAT AGG CGG CTT TCA TTT TTC C and for the
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hpark8-R primer is ACT CAG GCC CCA AAA ACG AG. Primers were generated in
house at the University of Western Ontario.

4.1.3
4.1.3.1

Behavioral Testing
Vibrissae-evoked forelimb placing

The forelimb placing test was performed as previously described and used as a measure
of movement initiation abilities (Schallert et al. 2002, Woodlee et al., 2005), a common
deficit observed in PD patients. Briefly, the experimenter holds the animal aloft by its
torso and brushes its vibrissae against the edge of the testing surface. This elicits a
forelimb placing response from the limb on the same side. Placing is quantified as the
percentage of correct responses or ‘hits’ elicited out of fifteen trials. Trials in which the
animal struggles or resists the experimenter’s grip are discounted. Animals were all
trained on this task prior to testing in order to ensure acclimation to the experimenter as
well as reduction in struggling behaviors.

4.1.3.2

Adjusting steps

The adjusting steps task has been extensively used to measure postural stability in rats
(Olsson et al., 1995, Chang et al., 1999, Fleming et al., 2009). The experimenter holds the
animal by its torso such that its hindlimbs are lifted above the testing surface. One
forelimb is then restrained so that the animal’s weight is entirely supported by the
remaining free forelimb, which is in contact with the testing surface. The experimenter
then moves the animal laterally across a testing surface with a distance of 70 cm. In order
to compensate for the movement of the body, the animal should make adjusting steps
with the weight-bearing forelimb. The average number of steps each animal makes over
five trials is recorded and used for analysis. Animals with nigrostriatal degeneration will
drag their forelimb instead of making the appropriate adjusting steps (Fleming et al.,
2012).

4.1.3.3

Footprint Analysis

Footprint analysis was performed in order to assess stepping patterns and abnormal gait
(Li et al., 2010). The rat’s paws were dipped in non-toxic paint and the rat was placed on
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a runway 110 cm long, 10 cm wide and with 25 cm high side walls. The runway led to
the rat’s homecage and rats were thus motivated to traverse the gangway. The floor of the
runway was lined with ordinary paper and the footprints marked on the paper were
analyzed. The distance between forepaws and the left and right stride were recorded.

4.1.3.4

Open Field Test

The open field test was used to measure general locomotor activity in wildtype and
transgenic rats. Each animal was placed in a square activity box (Med Associates Activity
Monitor, St. Albans, VT, USA) for 30 minutes per day, for two days. After each animal
finished testing, the activity boxes were cleaned with 70% ethanol to eliminate any odors
which may bias the next animal. Using the MedAssociates Activity Monitor software, we
analyzed the distance traveled and the number of rearing movements during the testing
interval. Exploratory rearing was used as an indirect measure of paucity of movement, as
previously shown (Landers et al., 2014).

4.1.3.5

Acoustic Startle Response and Sensory Gating

The acoustic startle response of these animals was tested using a protocol similar to those
previously described (Typlt et al., 2013). Startle testing was conducted in sound
attenuated startle boxes from Med Associates (MED ASR PRO1, St Albans, VT, USA).
Animals were placed in holders mounted on a movement sensitive platform within the
startle box. A transducer converted the vertical movement of the platform, induced by the
animal’s startle response, into a voltage signal. The maximum amplitude of the signal
was measured using Med Associates software (Startle Reflex Version 6, Med Associates,
St Albanks, VT, USA). On day 1, animals were acclimated to the startle box and
background noise (65 dB white noise) for 5 minutes in the morning and again for 5
minutes several hours later. On day 2, animals underwent an input-output (IO) test to
determine the appropriate gain setting for each animal. The IO function has an initial
stimulation at 65 dB (20 ms duration) and increased in 5 dB intervals to 120 dB. On day
3, animals were tested in two blocks for short term habituation and prepulse inhibition
respectively. Block 1 assessed habituation by presenting 30 trials of the startle pulse (105
dB white noise, 20 ms duration and 15 ms intertribal interval). Block 2 assessed prepulse
inhibition. In Block 2, there were seven different trial conditions (10 trials per condition)
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for a total of 70 trials. The trials presented the startle pulse alone, a low prepulse of 75 dB
(4 ms duration) before the startle pulse, and a high prepulse of 85 dB (4 ms duration)
before the startle pulse. The presentation of the prepulse and the startling pulse was
separated by three different interstimulus intervals (ISIs): 10 ms, 30 ms or 100 ms. The
trials were presented in pseudorandomized order. Animals were tested on both
habituation and prepulse inhibition as both responses are disrupted in PD patients
(Matsumoto et al., 1992; Zoetmulder et al., 2014).

4.1.3.6

Morris Water Maze

Both wildtype and transgenic animals underwent two versions of the Morris water maze
task to assess learning and memory, as previously described (Myoshi et al., 2002). This
task was conducted in a round tank, 146 cm in diameter and 58 cm deep, filled with
water. The water was colored with non-toxic blue paint to ensure opaqueness.
Throughout testing, the water temperature was monitored and maintained at 21°C. The
tank was divided into four equally sized quadrants and a circular acrylic escape platform
was placed in one of the quadrants. The escape platform was submerged in water by 2 cm
so that it was not visible to the animals. A camera mounted above the tank recorded the
movement of the animals in each trial. The Any-maze Behavior Tracking Software
(Stoelting Co., Wood Dale, IL, USA) was used to record the latency to reach the escape
platform and the time spent in the target quadrant.
All animals were first tested on the cued version of the water maze task. This consisted of
two training days with four trials on each day. In each trial, the animals were placed in
the water facing the tank wall and had to locate the escape platform, which was cued by a
yellow ball attached to the platform and protruding from the water. The trial was
completed when the animal either found the escape platform or 90 s had passed. If the
animal was unable to located the platform in 90 s, it was gently led to the platform.
Animals were allowed to remain on the escape platform for 15 s before being removed
and dried before the next trial. The initial position of the animal was the vertices of one of
the four quadrants and was different for each trial. The initial position was assigned
randomly and counterbalanced for the genotypes. The platform position was also changed
between each trial and was randomly assigned and counterbalanced.
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The animals were also tested on the spatial reference version of the water maze as
previous described (Miyoshi et al., 2002). This consisted of four training days with four
trials on each day. The experimental procedure was similar to the previous one, except
that the location of the platform was no longer cued. Instead, animals could utilize
external visual cues on the walls surrounding the tank to locate the platform. In addition,
the platform position was kept constant between trials and days. The four trials of the first
of the four training days were used as an indicator of spatial working memory.
On day 7, experimenters ran a 90 s probe trial without the platform. During this trial, the
time spent in the target quadrant was recorded for each animal.

4.2
Study 2: Testing Paraquat Vulnerability in aged
LRRK2R1441G transgenic rats
4.2.1

Vulnerability to Paraquat

In study 2, all animals were exposed to an acute sub-toxic Paraquat regimen, as
previously described, in order to assess vulnerability to toxins (Hutson et al., 2011).
Animals were separated into four groups: wildtype-saline (n=8), wildtype-Paraquat
(n=8), transgenic-saline (n=10), and transgenic-Paraquat (n=11). Animals received two
IP injections of Paraquat (10 mg/kg dissolved in 0.9% saline) or saline, with three days in
between injections. At the time of testing, animals were 14-16 months old. The toxin
dose used in this study was ¼ of that previously shown to cause dopaminergic cell death
in the substantia nigra in adult rats (Cicchetti et al., 2005). All animals underwent the
open field test immediately after receiving injections and 24 hours after injections. As
previously mentioned, MedAssociates Activity Monitor software was used to analyze the
number of rearing movements during a 30 minute testing interval.

4.2.2

q-RT PCR

Some transgenic rats were perfused with saline and samples for various brain regions
(cortex, substantia nigra, hippocampus), as well as liver and kidney were obtained and
frozen on ice. RNA was isolated using QIAzol Lysis Reagent (Qiagen, Germantown,
MD, CA) according to the manufacturer’s instructions. cDNA was synthesized using Life
Technologies high-capacity cDNA Reverse Transcription Kit (Life Technologies, Grand
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Island, NY, USA). Real time PCR assays were performed in triplicate on a 384 well
plate. The level of human LRRK2 mRNA was detected using TaqMan probe
Hs00411197_ml specific for human LRRK2 (Life Technologies, Grand Island, NY,
USA). The housekeeping gene GAPDH was detected using Rn01775763 (Life
Technologies, Grand Island, NY, USA) and was used as a reference gene.

4.2.3

Statistical Analysis

Mean values ± standard error are reported. Outliers, defined as data points three standard
deviations from the mean, were identified and removed from the data set. Comparisons of
genotype and treatment groups were performed using repeated measures ANOVA. IBM
SPSS Statistics 2.0 software was used for all statistical analyses. Results were considered
statistically significant at a p value of 0.05.
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5

Results
5.1
Study 1: Assessing PD-related phenotypes in
LRRK2R1441G transgenic rats

All animals were weighed before behavioral testing, at each age point. All rats
significantly increased their weight over time [ANOVA F(2,75)=378,90, p<0.001,
Greenhouse-Geisser correction], however there was no significant difference in weight
between transgenic LRRK2R1441G rats and their wildtype littermates [ANOVA
F(2,75)=0.63, p=0.52, Greenhouse-Geisser correction; Figure 4].

Figure 4: Rat Weight.
All rats were weighed before behavioral testing. There was no significant difference in
weight between wildtype and transgenic LRRK2R1441G rats at 3 (LRRK2R1441G: M=469.46,
SEM=7.58; WT: M=464.35, SEM=9.84), 6 (LRRK2R1441G: M=552.46, SEM=10.55; WT:
M=653.10, SEM=13.17), 9 (LRRK2R1441G: M=636.99, SEM=9.24; WT:M=653.96,
SEM=13.17), and 12 (LRRK2R1441G: M=676.46, SEM=13.37; WT: M=683.17,
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SEM=12.98) months of age [ANOVA F(2,75)=0.63, p=0.52, Greenhouse-Geisser
correction].

5.1.1
5.1.1.1

Motor Tests
Vibrissae-evoked forelimb placing

In order to assess movement initiation abilities, vibrissae-evoked forelimb placing
responses were measured in transgenic LRRK2R1441G rats and their wildtype littermates at
3, 6, 9 and 12 months of age. While a significant main effect of age was noted in forelimb
placing responses [ANOVA F(2,85)=8.14, p <0.05, Huynh-Feldt correction], no
genotype and age interaction was noted [ANOVA F(2,85)=0.37, p=0.71, Huynh-Feldt
correction]. Therefore, transgenic LRRK2R1441G did not significantly differ from wildtype
rats in vibrissae-evoked forelimb placing, suggesting intact movement initiation abilities
(Figure 5).

Figure 5: Vibrissae Evoked Forelimb Placing.
Vibrissae evoked forelimb placing was measured in transgenic LRRK2R1441G rats and
wildtype littermates. There was no significant difference in forelimb placing between
wildtype and transgenic LRRK2R1441G rats at 3 (LRRK2R1441G: M=0.87, SEM=0.02; WT:
M=0.87, SEM=0.02), 6 (LRRK2R1441G: M=0.91, SEM=0.06; WT: M=0.91, SEM=0.04), 9
(LRRK2R1441G: M=0.90, SEM=0.05; WT:M=0.98, SEM=0.01), and 12 (LRRK2R1441G:

36

M=0.93, SEM=0.05; WT: M=0.99, SEM=0.01) months of age [ANOVA F(2,85)=0.37,
p=0.71, Huynh-Feldt correction].

5.1.1.2

Adjusting steps

Postural stability in LRRK2R1441G rats was measured using the adjusting steps task. While
a small but significant main effect of age was noted in the number of adjusting steps
made [ANOVA F(3,102)=3.40, p <0.05, Huynh-Feldt correction], no genotype and age
interaction was noted [ANOVA F(3,102)=1.06, p=0.37, Huynh-Feldt correction].
Therefore, transgenic LRRK2R1441G rats did not significantly differ from wildtype rats in
the adjusting steps task, suggesting normal postural stability (Figure 6).

Figure 6: Adjusting Steps Task.
Performance on the adjusting steps task was measured in all animals. No significant
difference in adjusting steps was noted between transgenic LRRK2R1441G rats and
wildtype littermates at 3 (LRRK2R1441G: M=10.82, SEM=0.47; WT: M=12.15,
SEM=0.48), 6 (LRRK2R1441G: M=10.89, SEM=0.51; WT: M=11.56, SEM=0.58), 9
(LRRK2R1441G: M=11.28, SEM=0.73; WT:M=11.71, SEM=0.88), and 12 (LRRK2R1441G:
M=13.04, SEM=0.75; WT: M=12.50, SEM=0.85) months of age [ANOVA
F(2,85)=0.37, p=0.71, Huynh-Feldt correction].
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5.1.1.3

Footprint Analysis

Foot print analysis was conducted on all animals in order to assess gait patterns. A main
effect of age was noted in stride length of animals [ANOVA F(3,105)=37.36, p <0.05,
Huynh-Feldt correction]. Both right and left stride lengths were measured in all animals,
however, no main effect of side was noted [ANOVA F(1,39)=0.12, p=0.72, Huynh-Feldt
correction]. In addition, there was no interaction between age, side and genotype
[ANOVA F(3,117)=0.60, p=0.62, Huynh-Feldt correction].Therefore LRRK2R1441G rats
showed normal gait patterns as compared to wildtype controls (Figure 7).

Figure 7: Stride Length.
Stride length was calculated on each side (L indicates left side and R indicates right side)
in each animal and averaged within genotype. There was no significant difference in
stride length in transgenic LRRK2R1441G rats and wildtype littermates at 3 (LRRK2R1441G
Left M=14.30, SEM=0.29; LRRK2R1441G Right M=14.47, SEM=0.30; WT Left M=14.18,
SEM=0.27; WT Right M=14.31, SEM=0.31), 6 (LRRK2R1441G Left M=16.13, SEM=0.25;
LRRK2R1441G Right M=15.81, SEM=0.26; WT Left M=15.99, SEM=0.23; WT Right
M=15.82, SEM=0.26), 9 (LRRK2R1441G Left M=16.13, SEM=0.26; LRRK2R1441G Right
M=16.18, SEM=0.22; WT Left M=16.40, SEM=0.30; WT Right M=16.25, SEM=0.24)
and 12 (LRRK2R1441G Left M=16.39, SEM=0.24; LRRK2R1441G Right M=16.56,
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SEM=0.22; WT Left M=16.30, SEM=0.31; WT Right M=16.55, SEM=0.37) months of
age [ANOVA F(3,117)=0.60, p=0.62, Huynh-Feldt correction].

5.1.1.4

Open Field Test

Locomotor activity of transgenic LRRK2R1441G rats and wildtype controls was assessed on
the open field test. Animals were tested for two 30 minute sessions across two
consecutive days. Data presented here is calculated across both sessions. There was no
significant difference between transgenic and wildtype animals in the total distance
travelled during the two sessions [ANOVA F(3,102)=0.47, p=0.67, Huynh-Feldt
correction], although a main effect of age was noted [ANOVA F(3,102)=29.71,
p<0.001, Huynh-Feldt correction; Figure 8]. Similarly, no significant difference in
rearing behavior was noted between transgenic and wildtype rats [ANOVA
F(3,103)=0.79, p=0.49, Huynh-Feldt correction], although a main effect of age was
noted [ANOVA F(3,102)=19.33, p<0.001, Huynh-Feldt correction; Figure 9]. Finally,
there was no difference in maximal velocity of transgenic LRRK2R1441G rats and wildtype
controls [ANOVA F(3,117)=0.59, p=0.62; Figure 10].
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Figure 8: Total distance travelled in open field test.
Total distance travelled across testing sessions was calculated for all animals. No
significant difference in total distance travelled was noted between transgenic
LRRK2R1441G rats and wildtype littermates at 3 (LRRK2R1441G: M=3826.80, SEM=213.48;
WT: M=3892.54, SEM=330.19), 6 (LRRK2R1441G: M=2739.56, SEM=265.96; WT:
M=3036.17, SEM=267.54), 9 (LRRK2R1441G: M=2561.25, SEM=171.28;
WT:M=2494.14, SEM=174.34), and 12 (LRRK2R1441G: M=2094.07, SEM=156.20; WT:
M=2248.38, SEM=110.60) months of age [ANOVA F(3,102)=0.47, p=0.67, HuynhFeldt correction]. The distance travelled by all animals decreased as they aged [ANOVA
F(3,102)=29.71, p<0.001, Huynh-Feldt correction].
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Figure 9: Rearing behavior in open field test.
Rearing movements made by all animals was summed across testing sessions. No
significant difference in rearing movements was noted between transgenic LRRK2R1441G
rats and wildtype littermates at 3 (LRRK2R1441G: M=156.38, SEM=8.14; WT: M=128.53,
SEM=6.98), 6 (LRRK2R1441G: M=151.38, SEM=10.30; WT: M=132.76, SEM=10.28), 9
(LRRK2R1441G: M=167.50, SEM=14.72; WT:M=131.76, SEM=17.55), and 12
(LRRK2R1441G: M=81.58, SEM=10.36; WT: M=77.29, SEM=11.21) months of age
[ANOVA F(3,103)=0.79, p=0.49, Huynh-Feldt correction]. The total number of rearing
movements decreased as rats aged [ANOVA F(3,102)=19.33, p<0.001, Huynh-Feldt
correction].
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Figure 10: Maximal velocity in open field test.
Maximal velocity of transgenic and wildtype rats was calculated across testing sessions.
No significant difference in maximal velocity was noted between transgenic LRRK2R1441G
rats and wildtype littermates at 3 (LRRK2R1441G: M=72.99, SEM=3.96; WT: M=79.22,
SEM=6.01), 6 (LRRK2R1441G: M=73.65, SEM=3.54; WT: M=73.62, SEM=4.26), 9
(LRRK2R1441G: M=73.17, SEM=3.61; WT:M=68.88, SEM=3.68), and 12 (LRRK2R1441G:
M=65.87, SEM=3.79; WT: M=68.63, SEM=4.36) months of age [ANOVA
F(3,117)=0.59, p=0.62].

5.1.2
5.1.2.1

Cognitive Tests
Acoustic Startle Response and Sensory Gating

The acoustic startle response was measured in all rats in order to investigate sensory
gating mechanisms, including habituation and prepulse inhibition. Baseline startle
amplitude was calculated at the onset of sensory gating testing at each age point and was
not significantly different between transgenic and wildtype rats [ANOVA F(2,103)=0.32,
p=0.79, Huynh-Feldt correction; Figure 11]. Habituation scores were calculated by
dividing the average of the last five startle responses by the maximum of the first three
startle responses. Habituation scores of transgenic LRRK2R1441G rats and wildtype
littermates did not significantly differ [ANOVA F(3,102)=0.33, p=0.78, Huynh-Feldt
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correction; Figure 12]. Habituation was also measured by examining the attenuation of
startle response over time at each age point. At 3 months of age, a significant decrease in
startle amplitude was noted [ANOVA F(16,643)=3.29, p<0.001, Huynh-Feldt
correction], however there was no significant difference between transgenic and wildtype
rats [ANOVA F(16, 643)=0.68, p=0.82, Huynh-Feldt correction; Figure 13]. Similarly
habituation was observed in all animals at 6 [ANOVA F(12,476)=2.85, p<0.001,
Huynh-Feldt correction; Figure 14], 9 [ANOVA F(16,640)=1.91, p<0.05, Huynh-Feldt
correction; Figure 15] and 12 [ANOVA F(16,637)=2.97, p<0.001, Huynh-Feldt
correction; Figure 16] months of age but no significant difference between the genotypes
was observed [6 months ANOVA F(12,476)=0.78, p=0.67, Huynh-Feldt correction; 9
months ANOVA F(16,640)=1.04, p=0.42, Huynh-Feldt correction; 12 months ANOVA
F(16,637)=0.92, p=0.55, Huynh-Feldt correction].
In addition, prepulse inhibition was measured in all rats using two different prepulse
levels (75 dB and 85 dB) and three different interstimulus intervals (10 ms, 30 ms, 100
ms). At 3 months, a significant main effect of prepulse [ANOVA F(1,39)=32.10,
p<0.001; Figure 17 and Figure 18] and ISI was noted [ANOVA F(2,78)=10.28,
p<0.001], however there was no significant difference between transgenic and wildtype
rats [ANOVA F(2,78)=0.64, p=0.53]. Therefore at 3 months of age, all rats displayed
prepulse inhibition, with no significant difference between the two genotypes. Similarly,
prepulse inhibition was noted at 6 [ANOVA F(1,39)=61.53, p<0.001, Huynh-Feldt
correction; Figure 19 and Figure 20], 9 [ANOVA F(1,39)=30.40, p<0.001, Huynh-Feldt
correction; Figure 21 and Figure 22], and 12 months of age [ANOVA F(1,39)=29.83,
p<0.001, Huynh-Feldt correction; Figure 23 and Figure 24], however there was no
difference in the extent of inhibition between transgenic LRRK2R1441G rats and wildtype
controls [6 months ANOVA F(2,61)=0.228, p=0.74, Huynh-Feldt correction; 9 months
ANOVA F(2,78)=1.49, p=0.23, Huynh-Feldt correction; 12 months ANOVA
F(2,78)=1.59, p=0.21, Huynh-Feldt correction].
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Figure 11: Baseline startle amplitude.
Baseline startle amplitude was measured by calculating the maximum startle response
within the first three trials. Baseline startle amplitude did not differ between transgenic
LRRK2R1441G rats and wildtype littermates at 3 (LRRK2R1441G: M=1726.38, SEM=208.64;
WT: M=2224.03, SEM=298.55), 6 (LRRK2R1441G: M=2093.78, SEM=306.49; WT:
M=2641.25, SEM=342.10), 9 (LRRK2R1441G: M=2049.21, SEM=214.26;
WT:M=2337.33, SEM=396.26), and 12 (LRRK2R1441G: M=1685.81, SEM=227.55; WT:
M=2040.29, SEM=305.36) months of age [ANOVA F(3,103)=0.32, p=0.79].
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Figure 12: Habituation of the acoustic startle response.
Habituation scores were calculated for each rat by dividing the average of the last five
startle responses by the maximum of the first three startle responses and then averaged
across genotype. Habituation scores did not differ between transgenic LRRK2R1441G rats
and wildtype littermates at 3 (LRRK2R1441G: M=0.55, SEM=0.07; WT: M=0.67,
SEM=0.19), 6 (LRRK2R1441G: M=0.65, SEM=0.15; WT: M=0.52, SEM=0.08), 9
(LRRK2R1441G: M=0.64, SEM=0.09; WT:M=0.61, SEM=0.12), and 12 (LRRK2R1441G:
M=0.63, SEM=0.06; WT: M=0.65, SEM=0.10) months of age [ANOVA F(3,102)=0.33,
p=0.78].
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Figure 13: Habitation of the acoustic startle response at 3 months of age.
Startle amplitude was measured for each rat for 30 trials and then averaged by genotype.
While the rats did show a decrease in responsiveness over time [ANOVA
F(16,643)=3.29, p<0.001, Huynh-Feldt correction], there was no significant difference
between transgenic LRRK2R1441G rats and wildtype littermates [ANOVA F(16,
643)=0.68, p=0.82, Huynh-Feldt correction].

46

Figure 14: Habitation of the acoustic startle response at 6 months of age.
Startle amplitude was measured for each rat for 30 trials and then averaged by genotype.
While the rats did show attenuation of the startle response [ANOVA F(12,476)=2.85,
p<0.001, Huynh-Feldt correction], there was no significant difference between transgenic
LRRK2R1441G rats and wildtype littermates [ANOVA F(12,476)=0.783, p=0.67, HuynhFeldt correction].
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Figure 15: Habitation of the acoustic startle response at 9 months of age.
Startle amplitude was measured for each rat for 30 trials and then averaged by genotype.
While the rats did show attenuation of the startle response [ANOVA F(16,640)=1.91,
p<0.05, Huynh-Feldt correction], there was no significant difference between transgenic
LRRK2R1441G rats and wildtype littermates [ANOVA F(16,640)=1.04, p=0.415, HuynhFeldt correction].
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Figure 16: Habitation of the acoustic startle response at 12 months of age.
Startle amplitude was measured for each rat for 30 trials and then averaged by genotype.
While the rats did show attenuation of the startle response [ANOVA F(16,637)=2.97,
p<0.001, Huynh-Feldt correction], there was no significant difference between transgenic
LRRK2R1441G rats and wildtype littermates [ANOVA F(16,637)=0.92, p=0.55, HuynhFeldt correction].
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Figure 17: Prepulse inhibition of the acoustic startle response with 75 dB prepulse at
3 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G: M=0.23, SEM=0.04; WT: M=0.45,
SEM=0.13), 30 ms (LRRK2R1441G: M=0.33, SEM=0.05; WT: M=0.33, SEM=0.05), and
100 ms [LRRK2R1441G: M=0.38, SEM=0.05; WT:M=0.52, SEM=0.08; ANOVA
F(2,78)=0.64, p=0.53].
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Figure 18: Prepulse inhibition of the acoustic startle response with 85 dB prepulse at
3 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G M=0.22, SEM=0.04; WT: M=0.18,
SEM=0.06), 30 ms (LRRK2R1441G M=0.24, SEM=0.05; WT: M=0.22, SEM=0.04), and
100 ms [LRRK2R1441G M=0.26, SEM=0.04; WT:M=0.31, SEM=0.08; F(2,61)=0.228,
p=0.74; ANOVA F(2,78)=0.64, p=0.53].
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Figure 19: Prepulse inhibition of the acoustic startle response with 75 dB prepulse at
6 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G: M=0.37, SEM=0.04; WT: M=0.33,
SEM=0.05), 30 ms (LRRK2R1441G M=0.28, SEM=0.03; WT: M=0.31, SEM=0.04), and
100 ms [LRRK2R1441G M=0.34, SEM=0.05; WT:M=0.35, SEM=0.05; F(2,61)=0.228,
p=0.74; ANOVA F(2,61)=0.228, p=0.74, Huynh-Feldt correction].
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Figure 20: Prepulse inhibition of the acoustic startle response with 85 dB prepulse at
6 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G M=0.19, SEM=0.02; WT: M=0.16,
SEM=0.02), 30 ms (LRRK2R1441G M=0.17, SEM=0.01; WT: M=0.16, SEM=0.01), and
100 ms [LRRK2R1441G M=0.22, SEM=0.02; WT:M=0.21, SEM=0.03; F(2,61)=0.228,
p=0.74;ANOVA F(2,61)=0.228, p=0.74, Huynh-Feldt correction].
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Figure 21: Prepulse inhibition of the acoustic startle response with 75 dB prepulse at
9 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G: M=0.35, SEM=0.04; WT: M=0.50,
SEM=0.09), 30 ms (LRRK2R1441G: M=0.31, SEM=0.05; WT: M=0.32, SEM=0.04), and
100 ms [LRRK2R1441G: M=0.37, SEM=0.04; WT:M=0.45, SEM=0.07; F(2,61)=0.228,
p=0.74; ANOVA F(2,78)=1.49, p=0.23, Huynh-Feldt correction].
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Figure 22: Prepulse inhibition of the acoustic startle response with 85 dB prepulse at
9 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G: M=0.25, SEM=0.03; WT: M=0.24,
SEM=0.03), 30 ms (LRRK2R1441G: M=0.25, SEM=0.03; WT: M=0.25, SEM=0.03), and
100 ms [LRRK2R1441G: M=0.25, SEM=0.02; WT:M=0.23, SEM=0.03; F(2,61)=0.228,
p=0.74; ANOVA F(2,78)=1.49, p=0.23, Huynh-Feldt correction].
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Figure 23: Prepulse inhibition of the acoustic startle response with 75 dB prepulse at
12 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G: M=0.45, SEM=0.05; WT: M=0.48,
SEM=0.08), 30 ms (LRRK2R1441G: M=0.48, SEM=0.08; WT: M=0.33, SEM=0.03), and
100 ms [LRRK2R1441G: M=0.43, SEM=0.05; WT:M=0.45, SEM=0.06; F(2,61)=0.228,
p=0.74; ANOVA F(2,78)=1.59, p=0.21, Huynh-Feldt correction].

56

1.2

Startle Amplitude

1
0.8
0.6

WT

0.4

LRRK2

0.2
0
Baseline

10

30

100

Interstimulus Interval (ms)

Figure 24: Prepulse inhibition of the acoustic startle response with 85 dB prepulse at
12 months of age.
Prepulse inhibition of the startle response was measured at three different interstimulus
intervals: 10 ms, 30 ms, 100 ms. While all rats displayed prepulse inhibition of the startle
response, there was no significant difference between transgenic LRRK2R1441G rats and
wildtype littermates at an ISI of 10 ms (LRRK2R1441G: M=0.31, SEM=0.04; WT: M=0.24,
SEM=0.02), 30 ms (LRRK2R1441G: M=0.29, SEM=0.04; WT: M=0.26, SEM=0.04), and
100 ms [LRRK2R1441G: M=0.33, SEM=0.05; WT:M=0.29, SEM=0.07; F(2,61)=0.228,
p=0.74; ANOVA F(2,78)=1.59, p=0.21, Huynh-Feldt correction].

5.1.2.2

Morris Water Maze

All rats were tested on the Morris water maze in order to assess learning. In the cued
version of the test, latency to find the escape platform improved over training days at 9
months [ANOVA F(1,39)=31.73, p<0.001, Huynh-Feldt correction; Figure 25] and 12
months of age [ANOVA F(1,38)=7.11, p<0.05, Huynh-Feldt correction; Figure 29].
However at both 9 months [ANOVA F(1,39)=0.06, p=0.81, Huynh-Feldt correction] and
12 months [ANOVA F(1,38)=1.54, p=0.22, Huynh-Feldt correction], there was no
significant difference between transgenic LRRK2R1441G rats and wildtype controls. In the
spatial version of the test, training improved the mean latency to the platform in all rats at
9 [ANOVA F(2,66)=13.6, p<0.001, Huynh-Feldt correction; Figure 26] and 12 [ANOVA
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F(3,102)=15.34, p<0.001, Huynh-Feldt correction; Figure 30] months of age, however
no significant genotype difference was noted at either age point [9 months ANOVA F(2,
66)=0.93, p=0.39, Huynh-Feldt correction; 12 months ANOVA F(3,102)=1.09, p=0.35,
Huynh-Feldt correction]. In the working memory version of the test, performance
improved as a function of trials at 9 [ANOVA F(2,91)=9.7, p<0.001, Huynh-Feldt
correction; Figure 27] months and 12 [ANOVA F(2,68)=3.72, p<0.05, Huynh-Feldt
correction; Figure 31] months of age. However at 9 [ANOVA F(2, 91)=1.10, p=0.34,
Huynh-Feldt correction] and 12 [ANOVA F(2, 68)=1.15, p=0.32, Huynh-Feldt
correction] months of age, there was no significant difference between transgenic and
wildtype animals. Finally, a probe trial was conducted at the end of testing to assess the
amount of time spent in the target quadrant. At 9 months [t(39)=0.43, p=0.67; Figure 28]
and 12 months [t(38)=0.30, p=0.77; Figure 32] months of age, there was no significant
difference in time spent in target quadrant between transgenic LRRK2R1441G rats and their
wildtype littermates.
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Figure 25: Cued Version of the Morris Water Maze task at 9 months of age.
Latency to find the target platform was measured across two training days in the cued
version of the Morris water maze task. Performance on this task improved from training
day 1 (LRRK2R1441G: M=22.28, SEM=2.86; WT: M=21.49, SEM=3.30) to training day 2
(LRRK2R1441G: M=11.42, SEM=0.80; WT: M=9.63, SEM=0.81) in all rats [ANOVA
F(1,39)=31.73, p<0.001, Huynh-Feldt correction], however there was no significant
difference between transgenic LRRK2R1441G rats and wildtype controls [ANOVA
F(1,39)=0.06, p=0.81, Huynh-Feldt correction].

59

Figure 26: Spatial Reference Version of the Morris Water Maze task at 9 months of
age.
Latency to find the target platform was measured across four training days in the cued
version of the Morris water maze task. Performance on this task improved across training
days (LRRK2R1441G: M=9.40, SEM=0.71; WT: M=7.03, SEM=0.76) in all rats [ANOVA
F(2,66)=13.6, p<0.001, Huynh-Feldt correction], however there was no significant
difference between transgenic LRRK2R1441G rats and wildtype controls [ANOVA F(2,
66)=0.93, p=0.39, Huynh-Feldt correction].
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Figure 27: Working Memory Version of the Morris Water Maze task at 9 months of
age.
Latency to find the target platform was measured across four consecutive trials on one
day in the working memory version of the Morris water maze task. Performance on this
task improved across trials (LRRK2R1441G: M=15.45, SEM=2.04; WT: M=10.17,
SEM=1.66) in all rats [ANOVA F(2,91)=9.7, p<0.001, Huynh-Feldt correction],
however there was no significant difference between transgenic LRRK2R1441G rats and
wildtype controls [ANOVA F(2, 91)=1.10, p=0.34, Huynh-Feldt correction].
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Figure 28: Probe Trial in the Morris Water Maze at 9 months of age.
Time spent in the target quadrant was measured in a probe trial in LRRK2R1441G
(M=33.41, SEM=1.53) and WT rats (M=32.46, SEM=1.47). There was no significant
difference between the two genotypes [t(39)=0.43, p=0.67].
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Figure 29: Cued Version of the Morris Water Maze task at 12 months of age.
Latency to find the target platform was measured across two training days in the cued
version of the Morris water maze task. Performance on this task improved from training
day 1 (LRRK2R1441G: M=14.77, SEM=1.83; WT: M=12.26, SEM=1.65) to training day 2
(LRRK2R1441G: M=9.83, SEM=0.77; WT: M=10.45, SEM=1.76) in all rats [ANOVA
F(1,38)=7.11, p<0.05, Huynh-Feldt correction], however there was no significant
difference between transgenic LRRK2R1441G rats and wildtype controls [ANOVA
F(1,38)=1.54, p=0.22, Huynh-Feldt correction].
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Figure 30: Spatial Reference Version of the Morris Water Maze task at 12 months
of age.
Latency to find the target platform was measured across four training days in the cued
version of the Morris water maze task. Performance on this task improved by training day
4 (LRRK2R1441G M=6.65, SEM=0.55; WT: M=6.8, SEM=0.73) in all rats [ANOVA
F(3,102)=15.34, p<0.001, Huynh-Feldt correction], however there was no significant
difference between transgenic LRRK2R1441G rats and wildtype controls [ANOVA
F(3,102)=1.09, p=0.35, Huynh-Feldt correction].
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Figure 31: Working Memory Version of the Morris Water Maze task at 12 months
of age.
Latency to find the target platform was measured across four consecutive trials on one
day in the working memory version of the Morris water maze task. Performance on this
task improved by the last trial (LRRK2R1441G M=9.06, SEM=0.86; WT: M=6.8,
SEM=0.88) in all rats [ANOVA F(2,68)=3.72, p<0.05, Huynh-Feldt correction],
however there was no significant difference between transgenic LRRK2R1441G rats and
wildtype controls [ANOVA F(2, 68)=1.15, p=0.32, Huynh-Feldt correction].
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Figure 32: Probe Trial in the Morris Water Maze at 12 months of age.
Time spent in the target quadrant was measured in a probe trial in LRRK2R1441G
(M=39.73, SEM=1.39) and WT rats (M=39.06, SEM=1.80). There was no significant
difference between the two genotypes [t(38)=0.30, p=0.77].

5.2
Study 2: Testing Paraquat Vulnerability in aged
LRRK2R1441G transgenic rats
In order to assess gene environment interactions in PD, vulnerability to Paraquat was
measured in LRRK2R1441G transgenic rats at approximately 14-16 months of age.
Transgenic and wildtype rats were exposed to acute Paraquat poisoning and rearing
behavior was recorded (Figure 33). Animals received two injections of Paraquat or saline
and rearing behavior was measured immediately after each injection, 24 hours after each
injection and ten days post injection. A significant reduction in rearing behavior over
testing time points was noted in all animals [ANOVA F(3, 83)=9.30, p<0.001,
Greenhouse-Geisser correction]. As expected, there was no overall main effect of drug,
as a low dose of Paraquat was used in this experiment [ANOVA F(3, 83)=2.50, p=0.83,
Greenhouse-Geisser correction]. There was no interaction between time, drug and
genotype [ANOVA F(3, 83)=0.30, p=0.83, Greenhouse-Geisser correction]. Therefore,
LRRK2R1441G transgenic rats did not show vulnerability to Paraquat at the dose employed,
as compared to wildtype controls. In addition, univariate ANOVA analysis was
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conducted at each testing point. Immediately after injection 1, Paraquat exposed groups
displayed significantly reduced rearing movements [ANOVA F(1, 32)=5.51, p<0.05],
however the transgenic animals did not significantly differ from wildtype controls
[ANOVA F(1, 32)=0.033, p=0.857]. This effect was lost 24 hours post injection 1, and
no significant difference in rearing behavior was noted between groups exposed to
Paraquat or saline [ANOVA F(1, 28)=1.81, p=0.189]. Immediately following injection 2,
a significant main effect of drug was noted [ANOVA F(1, 28)=8.45, p<0.05], however
again, there was no significant difference between transgenic and wildtype controls
[ANOVA F(1, 28)=0.23, p=0.64]. 24 hours later, there was no difference between groups
exposed to Paraquat or saline [ANOVA F(1, 28)=2.73, p=0.06]. Ten days post injection
two, there was no significant main effect of drug [ANOVA F(1, 28)=1.10, p=0.30] or a
genotype and drug interaction [ANOVA F(1, 28)=0.37, p=0.55]. Overall, although
Paraquat had a short term effect on rearing behavior immediately following injections,
this effect was not selective for LRRK2R1441G rats, and was negated by ten days post
injection. Kaplan-Meier curves and a log rank (Mantel-Cox) test were conducted to
investigate survival estimates in transgenic LRRK2R1441G and wildtype rats (Figure 34).
There was no significant difference in survival time between transgenic and wildtype
animals [X2(1)=2.65, p=0.10]. Quantitative RT-PCR was conducted on surviving
transgenic animals at 18 months of age. Initial genotyping had revealed a genomic
presence of human LRRK2 (Figure 35), however RT-PCR results performed in surviving
transgenic rats at the end of the study revealed no detectable expression of human LRRK2
in the substantia nigra, cortex, hippocampus, liver or kidney (Table 1).
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Figure 33: Vulnerability to acute Paraquat poisoning.
Rearing behavior following acute Paraquat poisoning or exposure to saline was measured
in LRRK2R1441G and wildtype rats. All animals were tested immediately after injection 1,
24 hours after injection 1, immediately after injection 2, 24 hours after injection 2 and ten
days after the last injection. Overall, there was no significant interaction between drug
and genotype [ANOVA F(3, 83)=0.30, p=0.83, Greenhouse-Geisser correction].
Univariate ANOVA was conducted to investigate time point specific trends. Immediately
following injection 1 [ANOVA F(1, 32)=5.51, p<0.05] and injection 2 [ANOVA F(1,
28)=8.45, p<0.05], there was a reduction in rearing movements in Paraquat-exposed
groups. However, this trend was not specific to LRRK2R1441G transgenic rats [injection 1
ANOVA F(1, 32)=0.033, p=0.857;injection 2 ANOVA F(1, 28)=0.23, p=0.64] and was
negated 24 hours post injection [injection 1 ANOVA F(1, 28)=1.81, p=0.189; injection 2
ANOVA F(1, 28)=2.73, p=0.06]. Ten days following injections, no main effect of drug
[ANOVA F(1, 28)=1.10, p=0.30] or genotype drug interaction [ANOVA F(1, 28)=0.37,
p=0.55] in rearing behavior was noted.
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1.2

Survival Probability
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Figure 34: Survival curve for transgenic and wildtype rats.
Survival estimates were generated for LRRK2R1441G (M=17.91, SEM=0.38) and WT rats
(M=18.75, SEM=0.17). A log rank (Mantel-Cox) test revealed no significant differences
in survival between transgenic and wildtype animals [X2(1)=2.65, p=0.10].
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Figure 35: Genotype results for wildtype and transgenic animals.
Genotype results show positive bands, indicating presence of human LRRK2, as
compared to wildtype rats which do not express human LRRK2.
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Animal
ID

101

102

104

102

104

Genotype

DOB

7/26/2012

7/26/2012

7/26/2012

7/26/2012

7/26/2012

Tissue

LRRK2
expression

GAPDH
expression

Mean

Mean

SD

SD

Hippocampus

-

-

17.808

0.203

Substantia Nigra

-

-

18.217

0.287

Cortex

-

-

21.133

0.212

Kidney

-

-

19.127

0.142

Liver

-

-

18.912

0.096

Hippocampus

-

-

18.730

0.169

Substantia Nigra

-

-

19.639

0.025

Cortex

-

-

17.477

0.581

Kidney

-

-

18.105

0.372

Liver

-

-

18.790

0.161

Hippocampus

-

-

18.897

0.928

Substantia Nigra

-

-

21.802

4.886

Cortex

-

-

19.578

0.121

Kidney

-

-

19.308

0.360

Liver

-

-

22.004

0.194

Hippocampus

-

-

18.730

0.169

Substantia Nigra

-

-

19.639

0.025

Cortex

-

-

17.477

0.581

Kidney

-

-

18.105

0.372

Liver

-

-

18.790

0.161

Hippocampus

-

-

18.897

0.928

Substantia Nigra

-

-

21.802

4.886
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303

305

404

406

502

8/5/2012

8/5/2012

9/16/2012

9/16/2012

9/25/2012

Cortex

-

-

19.578

0.121

Kidney

-

-

19.308

0.360

Liver

-

-

22.004

0.194

Hippocampus

-

-

20.458

0.347

Substantia Nigra

-

-

20.347

0.961

Cortex

-

-

19.271

0.261

Kidney

-

-

18.998

1.423

Liver

-

-

21.391

0.311

Hippocampus

-

-

19.391

0.287

Substantia Nigra

-

-

20.340

1.455

Cortex

-

-

19.271

0.261

Kidney

-

-

18.901

0.102

Liver

-

-

21.164

0.351

Hippocampus

-

-

19.710

0.153

Substantia Nigra

-

-

20.246

0.051

Cortex

-

-

19.144

0.567

Kidney

-

-

20.316

0.669

Liver

-

-

23.021

3.470

Hippocampus

-

-

21.827

5.225

Substantia Nigra

-

-

20.121

0.083

Cortex

-

-

18.711

0.251

Kidney

-

-

19.768

0.282

Liver

-

-

22.133

0.081

Hippocampus

-

-

18.933

0.103

72

503

506

703

9/25/2012

9/25/2012

9/29/2012

Substantia Nigra

-

-

20.223

0.550

Cortex

-

-

20.541

0.069

Kidney

-

-

19.134

0.029

Liver

-

-

21.181

0.335

Hippocampus

-

-

23.215

0.079

Substantia Nigra

-

-

24.910

0.151

Cortex

-

-

23.557

0.258

Kidney

-

-

25.013

3.874

Liver

-

-

20.843

0.110

Hippocampus

-

-

18.746

0.283

Substantia Nigra

-

-

18.474

0.085

Cortex

-

-

21.564

0.106

Kidney

-

-

28.604

0.233

Liver

-

-

21.927

0.899

Hippocampus

-

-

21.522

0.130

Substantia Nigra

-

-

34.326

0.436

Cortex

-

-

21.379

0.127

Kidney

-

-

26.567

0.194

Liver

-

-

23.392

0.092

Table 1: qRT-PCR expression of wildtype and transgenic animals.
No detectable expression of human LRRK2 in surviving transgenic LRRK2R1441G rats in
the hippocampus, substantia nigra, cortex, kidney or liver was noted.
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Chapter 6

6

Discussion
6.1

Introduction

Animal models are critical tools for not only understanding LRRK2 pathobiology but
also PD aetiology and pathogenesis. In particular, models which carry PD related
mutations on the human LRRK2 gene can provide insight into LRRK2 function and the
mechanisms by which it mediates PD related dysfunction. Recently, bacterial artificial
chromosome (BAC) LRRK2 transgenic rodent models have been generated which allow
us to investigate the link between genetic mutations and development of PD. Here we
have characterized transgenic LRRK2R1441G BAC rats. These rats do not display PD
related motor or cognitive deficits by 12 months of age, and do not show increased
vulnerability to Paraquat poisoning as compared to age-matched wildtype controls.

6.2
Evidence from other transgenic models of LRRK2
mediated PD
Although to our knowledge no previous studies have examined PD phenotypes in
LRRK2R1441G transgenic BAC rats, our results are supported by recent studies in which
transgenic LRRK2 BAC mice fail to consistently reproduce cardinal features of PD.
Although Li et al. (2009) originally reported age-dependent, L-DOPA responsive,
progressive motor dysfunction in LRRK2R1441G BAC mice by 10 months of age,
subsequent studies in transgenic mice have been unable to reproduce these results.
Bichler et al. (2013) did not observe gross motor dysfunction in transgenic LRRK2R1441G
BAC mice by 10 months of age, although modest motor deficits were observed in
advanced age (21 months of age). These mice also did not display cognitive symptoms of
PD, including depression and anxiety-like behaviour and impaired learning and memory
(Bichler et al., 2013). However, gastrointestinal dysfunction, a common early non-motor
symptom of PD was noted in these mice by 6 months of age (Bichler et al., 2013).
Dranka et al. (2013) did not report gross motor abnormalities in LRRK2R1441G BAC mice,
although by 16 months of age, these mice did display deficits in motor coordination, an
early symptom of PD. Similarly, other classic transgenic LRRK2 mouse models have
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failed to show PD specific gross motor deficits (Li et al., 2010; Melrose et al., 2010;
Ramonet et al., 2011). The mild impairment of motor function seen in transgenic mice
models is further supported by the fact that these lines lack degeneration of nigrostriatal
dopaminergic neurons, although impaired dopaminergic neurotransmission was observed
(Li et al., 2009; Tong et al., 2009; Melrose et al., 2010; Dranka et al., 2013). Taken
together, these results suggest that transgenic LRRK2 rodents at best model early
phenotypes of Parkinson disease and do not recapitulate late stage PD phenotypes,
including the motor and cognitive deficits tested here.

6.3

Limitations of the Model

Parkinson disease is characterized by slow and progressive degeneration of the substantia
nigra and disruption of basal ganglia circuitry with advancing age. While neurotoxin
models which display disease outcomes have had great success in rats, the relatively short
life span of rats as compared to humans may make them imperfect models for studying
genetic forms of PD. A healthy laboratory rat can survive for approximately 3 years
while LRRK2 mediated PD is not apparent in humans until after 65 years of age. Indeed,
despite the discovery of many genetic mutations, the greatest known risk factor for PD
continues to be advanced age. The rats used in this study were 12 months of age, which is
considered ‘advanced’ age for rats (Quinn, 2005) but may not have been sufficient to
reproduce PD related phenotypes. Some researchers have argued that high levels of
transgene expression can induce neurological phenotypes within the life span of a rat.
Ramonet et al. (2011) tested four different transgenic mouse lines, expressing either the
G2019S mutation or the R1441C mutation and observed neuronal loss in advanced age in
only one line, in which transgene expression was more than 300% greater than the level
of endogenous LRRK2. However, in this case non-physiological levels of transgene
expression are used which while producing PD phenotypes may limit our ability to
translate animal research to human disease.
In addition, it is possible that because the transgene was constitutively expressed in these
rats, they were able to develop compensatory mechanisms which counteracted the toxic
effects of mutated LRRK2. Zhou et al (2011) found no behavioural phenotypes in rats
that constitutively expressed mutated LRRK2 however they did observe abnormal motor
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activity in rats with conditional adult onset expression of mutated LRRK2. Their results
suggest that rats are able to accommodate LRRK2’s toxic effects when it is constitutively
expressed. With this in mind, it is possible that future genetic models of PD should
consider the viral mediated gene transfer approach instead of the BAC approach. With
the viral mediated gene transfer approach, the mutated LRRK2 gene can be delivered to
rodents through a viral vector in adulthood, thus bypassing the development of
compensatory effects. This approach also allows researchers to target specific neuronal
populations, such as susbtantia nigra dopaminergic neurons, to better model the
degeneration seen in PD. Another advantage of the viral mediated gene transfer approach
is that it allows researchers to correlate transgene dosage (by modulating copy number of
transgene) with phenotype severity. Studies using this approach have already had success
in recapitulating cardinal features of PD. Lee et al (2010) created a mouse model of PD
expressing human G2019S LRRK2 using herpes simplex virus (HSV), which displayed
50% degeneration of nigral dopaminergic neurons. In addition a rat model generated by
Dusonchet et al (2011) expressing human G2019S LRRK2 showed a 20% reduction in
dopaminergic neurons. Viral models may allow us to recapitulate neurodegeneration
observed in PD patients, which has thus far been difficult to show in transgenic BAC
models.

6.4

Multiple Hit Hypothesis of PD

This study also explored the ‘multiple hit’ hypothesis of PD by investigating the
vulnerability of LRRK2R1441G transgenic rats to Paraquat poisoning. We exposed both
transgenic and wildtype rats to a low, acute dose of Paraquat exposure, in order to
examine synergistic effects of genetic mutations and environmental toxins on PD
development. As expected, the low dose of Paraquat used in this study did not have
lasting effects on rearing behaviour. Unexpectedly, transgenic rats did not differ from
wildtype controls in rearing behaviour following acute Paraquat exposure, suggesting a
lack of gene environment interaction between LRRK2 and Paraquat. Therefore, these
results did not provide support for the ‘multiple hit’ hypothesis. Nevertheless, a dosereponse study with higher doses would be necessary before this hypothesis can be
discounted. Our results are inconsistent with previous studies which show an interaction
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between PD-related mutations in the SNCA gene and environmental exposure in
mediating PD risk (Peng et al., 2010; Desplats et al., 2012; Nuber et al., 2014). Currently,
few studies have investigated gene environment interactions using PD related mutations
in the LRRK2 gene. However, one group did note altered transcriptional regulation of
neurogenesis related genes upon exposure to Paraquat in LRRK2G2019S mice (Desplats et
al., 2012). In addition, Ray et al (2014) found enhanced neurodegeneration when C.
elegans DA neurons expressing human α-syn or LRRK2 (G2019S) were exposed to a
bacterial metabolite. Alternatively, an epidemiological study by Chung et al. (2013) did
not find an interaction between environmental exposure and LRRK2 genes. Our results in
the context of previous literature suggest that further investigation is necessary in order to
confirm the interaction between PD-related LRRK2 mutations and environmental
exposure. One explanation is that previous animal studies have largely looked at
neuropathology and have not examined motor dysfunction. As previously mentioned,
significant neurodegeneration is necessary before the onset of motor symptoms. It is
possible that our rats simply did not develop motor symptoms at the time of testing and
that continued exposure to Paraquat would have induced a motor phenotype in
LRRK2R1441G rats. The Paraquat paradigm used in this experiment was modeled after an
earlier study investigating the interaction between traumatic brain injury and exposure to
Paraquat (Hutson et al., 2011). This study reported a robust interaction between traumatic
brain injury and Paraquat exposure on rearing behaviour in rats. However, it is possible
that because our LRRK2 mutation did not cause neurodegeneration to the extent
described in the TBI rats (Hutson et al., 2011), a more lethal dose of Paraquat was
required to induce PD related motor phenotypes.

6.5

Methodological Considerations

An important methodological limitation of this study is that there were no detectable
levels of transgene expression in surviving LRRK2R1441G transgenic rats. While transgenic
rats did display genomic LRRK2 in initial genotyping PCR results, this gene seemed to be
not transcribed to a detectable level as displayed by quantitative RT-PCR results. One
limitation of the transgenic approach is that due to random integration of the transgene,
positional effects can occur. Position effects refer to the phenomenon whereby transgene
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expression is influenced by the integration site. BAC constructs are large genomic inserts
and due to their size (~200 kb) allow the inclusion of endogenous regulatory elements,
which should greatly reduce the probability of position effects. However the lack of
transgene expression noted in this model suggests that transgene insertion, even with the
BAC approach, was not stable. Position effects can include lack of transgene expression
and extinction of transgene expression in successive generations. As the rats tested in this
study were bred from an original pair obtained from Taconic, it is possible that transgene
expression diminished due to successive breeding. Another consideration is that only rats
which survived until the end of the study were tested for transgene expression. Indeed the
animals most likely to show levels of transgene expression were those who did not
survive after the administration of Paraquat as it is possible that insertion of the LRRK2
gene impacted viability. Interestingly, post-mortem analysis conducted on LRRK2 rats
which did not survive until the end of the study indicates morphology consistent with
hemopoietic tumors. A recent study by Ruiz-Martinez et al (2014) reported a higher
prevalence of hematological cancers in patients carried the R1441G mutation.

6.6

Summary of findings

In this study, we characterized transgenic BAC rats carrying the R1441G mutation on the
human LRRK2 gene. Rats underwent motor and cognitive tests in order to assess the
variety of behavioural phenotypes observed in Parkinson disease. Transgenic
LRRK2R1441G rats did not display any motor or cognitive deficits reminiscent of Parkinson
disease by 12 months of age. These results are consistent with studies performed on
transgenic mice which also fail to reproduce gross motor abnormalities (Li et al., 2010;
Melrose et al., 2010; Ramonet et al., 2011; Bichler et al., 2013; Dranka et al., 2013).
Together these results suggest that the genetic mutation itself is insufficient to reproduce
PD phenotypes in these rats. Also, transgenic LRRK2R1441G rats were tested for
vulnerability to Paraquat poisoning, in order to assess the hypothesis that exposure to
environmental toxins works synergistically with a genetic predisposition to PD to
produce disease phenotypes. Our results show that LRRK2R1441G rats did not display
increased vulnerability to the neurotoxin Paraquat, as compared to wildtype controls.
This may be due to the low dose of Paraquat used in this study and the lack of transgene
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expression. Overall, our results indicate that these transgenic BAC LRRK2R1441G rats are
not a viable model of Parkinson disease.
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Neuroscience Association 33rd Annual Meeting, Waterloo, Ontario, Canada.
Shaikh, K.T., Walewski, C., Yang, A., Schmid, S. (2013, March). Motor characteristics of a
transgenic LRRK2 rat model of Parkinson disease. Poster presented at the London Health
Research Day, London, Ontario, Canada.
Barros, W., Shaikh, K.T., Schmid, S. (2013, March). Cognitive characteristics of a transgenic
LRRK2 rat model of Parkinson disease. Poster presented at the London Health Research Day,
London, Ontario, Canada.
Shaikh, K.T., Walewski, C., Yang, A., Schmid, S. (2013, March). Investigating a transgenic
LRRK2 rat model of Parkinson disease. Poster presented at the Western Research Forum,
London, Ontario, Canada.
Barros, W., Shaikh, K.T., Schmid, S. (2013, March). Cognitive abilities of a transgenic LRRK2
rat model of Parkinson disease. Poster presented at the Western Research Forum, London,
Ontario, Canada.
Shaikh, K.T., Schmid, S. (2011, April). Gender differences in modulations of acoustic startle
response in Sprague Dawley rats. Poster presented at the Ontario Undergraduate
Neuroscience Conference, Hamilton, Ontario, Canada.
Shaikh, K.T., Schmid, S. (2011, May). Gender differences in modulations of acoustic startle
response in Sprague Dawley rats. Poster presented at the 31st annual meeting of the
Southern Ontario Neuroscience Association, Guelph, Ontario, Canada.

Conference Talks
Shaikh, K.T., Schmid, S. (2011, March). Gender differences in modulations of acoustic startle
response in Sprague Dawley rats. Symposium Presentation, Western Undergraduate
Research Forum, London, Ontario, Canada.

Honors & Awards






Ontario Graduate Scholarship 2014-2015
Grand Challenges in Parkinson Disease Conference – 1st Place Poster
Competition 2013
Western Research Forum – 1st Place Poster Competition 2013
Western Graduate Research Scholarship 2012-2014
University of Western Ontario – Continuing Scholarship 2008
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Governor General’s Academic Medal 2008
Canadian Federation of University Women Scholarship 2008
The University of Toronto National Book Award 2008
The Linscott Scholarship 2008

Research Training
Sept 08 – April 12



Sept 11- April 12

University of Western Ontario [London, Ontario]
Research Assistant, Schmid Lab, Neurobiology
Researched the mechanisms of acoustic startle modulations
Observed and practiced several lab techniques, including rodent
brain slicing, brain mapping, and analyzing behavioural responses

University of Western Ontario [London, Ontario]
Research Assistant, Zarbatany Lab, Developmental Psychology



May 10 – Sept 10

Investigated the effect of peer group relations on children’s
psychological adjustment
Determined positive affect in children as a function of their social
status

Ottawa Hospital Research Institute [Ottawa, Ontario]
Research Assistant, Kothary Lab, Regenerative Medicine



Investigated muscular defects of spinal muscular atrophy through
the isolation of tibialis anterior muscle in mice
Practiced several lab techniques, including PCR, genotyping, and
dissection

Professional Service
Teaching Experience
Sept 12-May 12;
(ACB4511)
Sept 13- Jan 14

Teaching Assistant – Integrative Neuroscience Course
University of Western Ontario



Graded course work, as well as assisted students with course
relevant material and assignments

Clinical Experience
May 14 - Sept 14

Intensive Behaviour Intervention – Thames Valley Children’s
Centre
Junior Therapist



May 13- April 14

Taught basic skills to an autistic child in a direct one-on-one
approach using Applied Behaviour Analysis principles

Intensive Multi-Treatment Intervention Program
Play Therapy Volunteer
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Provided play therapy for an autistic child, focusing on increasing
social behaviours through a cognitive behavioural approach

